arrow
P

Paul G. Leonard

Royal Hospital for Children and Young People
H指数:26
被引数:2,359

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world impact of nirsevimab immunisation and maternal RSV vaccination against respiratory disease on emergency department attendances and admissions: a multinational retrospective analysis

nirsevimab免疫接种和孕产妇RSV疫苗接种对呼吸系统疾病对急诊科就诊和入院的现实影响: 一项跨国回顾性分析

2026-02-030
OAAI
Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor
2021-10-1323
PREAI
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme

发现IACS-9779和IACS-70465作为靶向吲哚胺2,3-双加氧酶1 (IDO1) 脱辅酶的有效抑制剂

2021-07-2217
PREAI
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers (vol 2, pg 1413, 2020)
2020-12-180
OAAI
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

变构SHP2抑制剂,IACS-13909克服了对奥希替尼的EGFR依赖性和EGFR非依赖性耐药机制

2020-11-0362
OAAI
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

发现具有优异药代动力学和理化特性的临床阶段选择性Glutaminase-1 (GLS-1) 抑制剂IPN60090

2020-10-2962
OAAI
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R
2020-07-2913
PREAI
Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance
2019-12-011
PRE
IACS-9779, a development candidate that inhibits 2,3-dioxygenase (IDO) activity by blocking heme incorporation into IDO apoenzyme
2019-07-011
PRE
Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation
2019-01-0145
OA
Discovery of an imidazopyridine series of potent human IDO1 inhibitors with robust target engagement in a preclinical tumor model
2018-07-010
PRE